Trials / Unknown
UnknownNCT03089099
Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer
Development of a Prognostic Model for High Volume Metastatic Castration-Resistant Prostate Cancer Patients by Sequentially Analyzing the Expression of Molecular Markers in Circulating Tumor Cells
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- Male
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
As prostate cancer progresses into castration-resistant stage from initial hormone-sensitive status, the biological behavior of tumor cells that dissociated from primary lesions changed. Considered a "liquid biopsy," these circulating tumor cells (CTCs) can show how a patient's cancer responded to treatments. The purpose of this study is to determine whether sequentially analyzing the expression of molecular markers in high volume circulating tumor cells in metastatic castration-resistant prostate cancer patients can predict the therapeutic effects and outcomes of these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Blood drawing | Blood drawing |
Timeline
- Start date
- 2017-04-24
- Primary completion
- 2019-04-01
- Completion
- 2019-04-01
- First posted
- 2017-03-24
- Last updated
- 2017-05-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03089099. Inclusion in this directory is not an endorsement.